Alisson Paulino Trevizol1,2, Kyle W Goldberger3, Benoit H Mulsant1, Tarek K Rajji1,2, Jonathan Downar1,4, Zafiris J Daskalakis1,2, Daniel M Blumberger1,2. 1. Department of Psychiatry, University of Toronto, Toronto, Canada. 2. Temerty Centre for Therapeutic Brain Intervention and Campbell Family Research Institute, Centre for Addiction and Mental Health, Toronto, Canada. 3. Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Canada. 4. MRI Guided rTMS Clinic, Toronto Western Hospital, University Health Network, Toronto, Canada.
Abstract
BACKGROUND: The management of late-life depression is challenged by high rates of treatment-resistance and adverse effects, along with medical comorbidities and polypharmacy. Together with the limited data on managing treatment-resistant depression in older adults, there is a need for investigating the efficacy of nonpharmacological treatment strategies. Repetitive transcranial magnetic stimulation (rTMS) is one modality that may better serve this patient population. METHODS: The present study examines data from two previous clinical trials (NCT00305045 and NCT01515215) to explore the efficacy of bilateral and unilateral high-frequency left-sided (HFL) rTMS in older adults suffering from treatment-resistant depression. A total of 43 adults aged 60 or older with a current major depressive episode were randomized to bilateral sequential, unilateral HFL, or sham. Bilateral sequential stimulation involved low-frequency (1 Hz) right dorsolateral prefrontal cortex (DLPFC) stimulation followed immediately by high-frequency (10 Hz) left DLPFC. The unilateral condition was HFL stimulation alone, and the placebo condition was either HFL or sequential bilateral form of sham. The primary outcome was remission of depression. RESULTS: Participants receiving bilateral rTMS experienced greater remission rates (40%) compared with unilateral (0%) or sham (0%) groups. Response to rTMS in the Hamilton Depression Rating Scale scores similarly favored the efficacy of bilateral rTMS. CONCLUSION: This study suggests that sequential bilateral treatment may be an optimal form of rTMS when used for treatment-resistant depression in older adults. Further large-scale comparative effectiveness trials of bilateral rTMS in this population are warranted.
RCT Entities:
BACKGROUND: The management of late-life depression is challenged by high rates of treatment-resistance and adverse effects, along with medical comorbidities and polypharmacy. Together with the limited data on managing treatment-resistant depression in older adults, there is a need for investigating the efficacy of nonpharmacological treatment strategies. Repetitive transcranial magnetic stimulation (rTMS) is one modality that may better serve this patient population. METHODS: The present study examines data from two previous clinical trials (NCT00305045 and NCT01515215) to explore the efficacy of bilateral and unilateral high-frequency left-sided (HFL) rTMS in older adults suffering from treatment-resistant depression. A total of 43 adults aged 60 or older with a current major depressive episode were randomized to bilateral sequential, unilateral HFL, or sham. Bilateral sequential stimulation involved low-frequency (1 Hz) right dorsolateral prefrontal cortex (DLPFC) stimulation followed immediately by high-frequency (10 Hz) left DLPFC. The unilateral condition was HFL stimulation alone, and the placebo condition was either HFL or sequential bilateral form of sham. The primary outcome was remission of depression. RESULTS:Participants receiving bilateral rTMS experienced greater remission rates (40%) compared with unilateral (0%) or sham (0%) groups. Response to rTMS in the Hamilton Depression Rating Scale scores similarly favored the efficacy of bilateral rTMS. CONCLUSION: This study suggests that sequential bilateral treatment may be an optimal form of rTMS when used for treatment-resistant depression in older adults. Further large-scale comparative effectiveness trials of bilateral rTMS in this population are warranted.
Authors: Felipe Fregni; Marco A Marcolin; Martin Myczkowski; Revital Amiaz; Gary Hasey; Demetrio O Rumi; Moacyr Rosa; Sergio P Rigonatti; Joan Camprodon; Michaela Walpoth; Jaclyn Heaslip; Leon Grunhaus; Armand Hausmann; Alvaro Pascual-Leone Journal: Int J Neuropsychopharmacol Date: 2005-11-23 Impact factor: 5.176
Authors: E J Lenze; J C Rogers; L M Martire; B H Mulsant; B L Rollman; M A Dew; R Schulz; C F Reynolds Journal: Am J Geriatr Psychiatry Date: 2001 Impact factor: 4.105
Authors: Mark S George; Sarah H Lisanby; David Avery; William M McDonald; Valerie Durkalski; Martina Pavlicova; Berry Anderson; Ziad Nahas; Peter Bulow; Paul Zarkowski; Paul E Holtzheimer; Theresa Schwartz; Harold A Sackeim Journal: Arch Gen Psychiatry Date: 2010-05
Authors: Cheng-Chen Chang; Shun-Chieh Yu; Douglas R McQuoid; Denise F Messer; Warren D Taylor; Kulpreet Singh; Brian D Boyd; K Ranga R Krishnan; James R MacFall; David C Steffens; Martha E Payne Journal: Psychiatry Res Date: 2011-05-18 Impact factor: 3.222
Authors: Daniel M Blumberger; Jerome J Maller; Lauren Thomson; Benoit H Mulsant; Tarek K Rajji; Missy Maher; Patrick E Brown; Jonathan Downar; Fidel Vila-Rodriguez; Paul B Fitzgerald; Zafiris J Daskalakis Journal: J Psychiatry Neurosci Date: 2016-06 Impact factor: 6.186
Authors: Urs P Mosimann; Wolfgang Schmitt; Benjamin D Greenberg; Markus Kosel; René M Müri; Magdalena Berkhoff; Christian W Hess; Hans U Fisch; Thomas E Schlaepfer Journal: Psychiatry Res Date: 2004-04-30 Impact factor: 3.222
Authors: Andre R Brunoni; Anna Chaimani; Adriano H Moffa; Lais B Razza; Wagner F Gattaz; Zafiris J Daskalakis; Andre F Carvalho Journal: JAMA Psychiatry Date: 2017-02-01 Impact factor: 21.596
Authors: Daniel M Blumberger; Benoit H Mulsant; Kevin E Thorpe; Shawn M McClintock; Gerasimos N Konstantinou; Hyewon H Lee; Sean M Nestor; Yoshihiro Noda; Tarek K Rajji; Alisson P Trevizol; Fidel Vila-Rodriguez; Zafiris J Daskalakis; Jonathan Downar Journal: JAMA Psychiatry Date: 2022-09-21 Impact factor: 25.911
Authors: Shawn M McClintock; Lex Minto; David A Denney; K Chase Bailey; C Munro Cullum; Vonetta M Dotson Journal: Curr Psychiatry Rep Date: 2021-07-13 Impact factor: 8.081
Authors: Geke M Overvliet; Rebecca A C Jansen; Anton J L M van Balkom; Dilene C van Campen; Mardien L Oudega; Ysbrand D van der Werf; Eric van Exel; Odile A van den Heuvel; Annemiek Dols Journal: Int J Geriatr Psychiatry Date: 2020-11-06 Impact factor: 3.485